Company: BACC
Filing Date: 2025-03-26
Form Type: DRS
Source: 0001185185-25-000217
Chunk: 11

Company: Blue Acquisition Corp/Cayman
Filing Date: 2025-03-26
Form: DRS
Chunk 11
---
.20 per unit (including any units sold pursuant to the underwriters’                                                             
 option to purchase additional units), or $3,000,000 in the aggregate (or $3,450,000 if the underwriters’ over-allotment option is           
 exercised in full), payable to the underwriters upon the closing of this offering. Also includes $0.40 per unit on all units sold including 
 those sold pursuant to the underwriters’ option to purchase additional units, or $6,000,000 in the aggregate (or $6,900,000 in the          
 aggregate if the underwriters’ over-allotment option is exercised in full) payable to the underwriters for deferred underwriting            
 commissions to be deposited into a trust account located in the United States and released to the underwriters for their own account        
 only upon the completion of an initial business combination. The underwriters have received and will receive compensation in addition       
 to the underwriting discount, including 150,000 Class A ordinary shares, which we refer to herein as the “representative shares.”           
 See also “Underwriting” for a description of compensation and other items of value payable to the underwriters.                             |

Of the proceeds we receive from this offering and the sale of the private placement units described in this prospectus, $150,750,000, or $173,362,500 if the underwriters’ overallotment option is exercised in full ($10.05 per unit in either case), will be placed into a U.S.-based trust account with Continental Stock Transfer & Trust Company acting as trustee.

Because our sponsor acquired the founder shares at a nominal price, our public shareholders will incur an immediate and material dilution upon the closing of this offering. Further, the Class A ordinary shares issuable in connection with the conversion of the founder shares may result in material dilution to our public shareholders due to the anti-dilution rights of our founder shares that may result in an issuance of Class A ordinary shares on a greater than one-for-one basis upon conversion. See the section titled “ Risk Factors — Risks Relating to our Securities — The nominal purchase price paid by our sponsor for the founder shares may result in material dilution to the implied value of your public shares upon the consummation of our initial business combination, and our sponsor is likely to make a substantial profit on its investment in us in the event we consummate an initial business combination, even if the business combination causes the trading price of our ordinary shares to materially decline”